ADVERTISEMENT
Microbot Medical Signs Phase 2 Collaboration Agreement with Corewell Health to Advance Remote Telesurgery Using the Liberty Endovascular Robotic System
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system
The agreement follows the successful completion of Phase 1 which evaluated the viability of LIBERTY as a remote telesurgery platform
The objective of Phase 2 is to develop and demonstrate new telesurgery capabilities by performing simulated interventional procedures between two facilities within the Corewell Health system
Microbot Medical, Inc., News
BRAINTREE, Mass. — Microbot Medical Inc, developer of the innovative LIBERTY® Endovascular Robotic System, announces that it entered into a Phase 2 collaboration agreement with Corewell Health™ that will continue their collaboration to advance remote telesurgery for endovascular procedures. The Company had previously announced positive results from the first phase, which demonstrated LIBERTY’s technical capabilities and outlined potential future applications in a range of endovascular interventions, including the feasibility of LIBERTY to support the remote telesurgery project.
During Phase 2, the Company and Corewell Health will work together to develop the capabilities to perform simulated cardiovascular interventional procedures with LIBERTY across two sites within the Corewell Health system which are 5 miles apart.
The project is led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in West Michigan. Following the completion of Phase 1, Dr. Madder and colleagues published a manuscript in the Journal of the American College of Cardiology: Cardiovascular Interventions, highlighting the Technical Success of Coronary Guidewire and Stent Delivery Using a Novel Miniaturized Robotic System in a Pre-Clinical Study.
“Incorporating telesurgery capabilities is an important part of our long-term strategy for LIBERTY,” said Harel Gadot, CEO, President and Chairman of Microbot Medical. “We believe that physicians in the U.S. and around the globe want to increase access to care for patients in remote locations, and we are excited to continue our collaboration with Corewell Health and Dr. Madder on this next phase of development.”
Dr. Madder’s manuscript is available at: https://doi.org/10.1016/j.jscai.2024.102148
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a clinical- stage medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The Investigational LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment, while reducing radiation exposure and physician strain. The Company believes the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
Further information about Microbot Medical is available at http://www.microbotmedical.com.
Find More:
Cardiovascular Ambulatory Surgery Centers (ASCs) Topic Center
The Latest Clinical & Industry News
Case Reports
Grand Rounds With Morton Kern, MD
Podcasts: Cath Lab Conversations
Go to Cath Lab Digest's current issue page
